Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00148512
Status:
COMPLETED
Last Update Posted:
2013-10-29
First Post:
2005-09-07
Brief Title:
A Randomized Double-blind Placebo-controlled Five Parallel Groups Efficacy and Safety Study of NS 2330 Tesofensine 0125 mg 025 mg 05 mg and 10 mg Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations
Sponsor:
Organization:
Boehringer Ingelheim
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
254
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: